Horizon's Medical Marijuana

HMMJ-T

Analysis and Opinions about HMMJ-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
November 4, 2019
He's never liked marijuana stocks. The hype wasn't justified and they got way ahead of themselves. This will be regulated like alcohol which means tight returns.
He's never liked marijuana stocks. The hype wasn't justified and they got way ahead of themselves. This will be regulated like alcohol which means tight returns.
Richard Croft
President, R.N. Croft Financial Group Inc.
Price
$10.500
Owned
Unknown
DON'T BUY
DON'T BUY
September 6, 2019
Marijuana stocks There has been a sell off because of Canntrust and no one is making money. There will be a lot of research to be done on the benefits. However, the best days to make profit here are probably behind us.
Marijuana stocks There has been a sell off because of Canntrust and no one is making money. There will be a lot of research to be done on the benefits. However, the best days to make profit here are probably behind us.
Darren Sissons
Vice President and Partner, Campbell Lee & Ross
Price
$15.200
Owned
No
BUY WEAKNESS
BUY WEAKNESS
September 5, 2019
Anytime you are investing in an area with such massive potential growth opportunities, you will see volatility. If you buy a little and more yet in corrections, it is a way to play it. Wait for good stiff corrections.
Anytime you are investing in an area with such massive potential growth opportunities, you will see volatility. If you buy a little and more yet in corrections, it is a way to play it. Wait for good stiff corrections.
Mike Philbrick
President, ReSolve Asset Management
Price
$14.950
Owned
Unknown
BUY
BUY
August 1, 2019

HMMJ vs. HMUS. A monstrous opportunity, but you're going to suffer volatility. Go slow, get in over time, and keep it to a smaller proportion of your portfolio. Market weighted. The US exposure is to companies operating legally, and there can't be any recreational use. With HMUS, you're tapping into a bigger market. For example, Charlotte's Web is planning to sell CBD infused products through Kroeger. This scale dwarfs the whole Canadian market. Valuations are high because of the growth potential. If you're a marijuana investing aficionado, you'd want to own both.

HMMJ vs. HMUS. A monstrous opportunity, but you're going to suffer volatility. Go slow, get in over time, and keep it to a smaller proportion of your portfolio. Market weighted. The US exposure is to companies operating legally, and there can't be any recreational use. With HMUS, you're tapping into a bigger market. For example, Charlotte's Web is planning to sell CBD infused products through Kroeger. This scale dwarfs the whole Canadian market. Valuations are high because of the growth potential. If you're a marijuana investing aficionado, you'd want to own both.

Mike Philbrick
President, ReSolve Asset Management
Price
$15.810
Owned
Unknown
COMMENT
COMMENT
June 12, 2019
Any vice will do well, and so will this. Horizon makes great ETFs. That said, ETF's aren't always the best. Instead of buying the weed basket, buy the leader--Canopy.
Any vice will do well, and so will this. Horizon makes great ETFs. That said, ETF's aren't always the best. Instead of buying the weed basket, buy the leader--Canopy.
Terry Shaunessy
President & portfolio manager, Shaunessy Investment Counsel
Price
$19.085
Owned
Unknown
DON'T BUY
DON'T BUY
June 3, 2019
Companies on this don't have any earnings. With out earnings he doesn't want it.
Companies on this don't have any earnings. With out earnings he doesn't want it.
John Hood
President & Portfolio Manager, J. C Hood Investment.
Price
$17.990
Owned
No
COMMENT
COMMENT
May 9, 2019
How does this pay a yield if weed stocks don't? It does pay a dividend, perhaps from capital gains from buying and selling those weed stocks within the ETF. He doesn't think cannabis will be an exciting industry, but will wind up like the liquor business.
How does this pay a yield if weed stocks don't? It does pay a dividend, perhaps from capital gains from buying and selling those weed stocks within the ETF. He doesn't think cannabis will be an exciting industry, but will wind up like the liquor business.
Richard Croft
President, R.N. Croft Financial Group Inc.
Price
$19.970
Owned
Unknown
BUY WEAKNESS
BUY WEAKNESS
April 16, 2019
This has the potential for massive growth in 20 years considering the medical applications of cannabis, but this space also has massive volatility. Buy during large declines and tiptoe in. Society is in the process of accepting marijuana. This is a sea change now.
This has the potential for massive growth in 20 years considering the medical applications of cannabis, but this space also has massive volatility. Buy during large declines and tiptoe in. Society is in the process of accepting marijuana. This is a sea change now.
Mike Philbrick
President, ReSolve Asset Management
Price
$20.330
Owned
Unknown
COMMENT
COMMENT
April 15, 2019
There is some downside pressure on HMMJ-T. At the $14 or $17 range there is resistance. Who knows what the effect would be if the government changes in October. [Caller asked about TLRY] He sees $34 as a target on TLRY-T as there is nothing to hold it higher.
There is some downside pressure on HMMJ-T. At the $14 or $17 range there is resistance. Who knows what the effect would be if the government changes in October. [Caller asked about TLRY] He sees $34 as a target on TLRY-T as there is nothing to hold it higher.
Hap (Robert) Sneddon FCSI
Chief Portfolio Manager & Founder, Castlemoore Inc.
Price
$19.890
Owned
Unknown
WAIT
WAIT
March 25, 2019
X-dividend date coming up. After the next economic downturn, this will be a sector to invest in and forget it for a decade. At this point he does not see it goes above the recent highs. Don't invest in it now. You might trade it.
X-dividend date coming up. After the next economic downturn, this will be a sector to invest in and forget it for a decade. At this point he does not see it goes above the recent highs. Don't invest in it now. You might trade it.
Larry Berman CFA, CMT, CTA
Chief Investment Officer, Partner, ETF Capital Management Inc.
Price
$22.540
Owned
Unknown
COMMENT
COMMENT
March 12, 2019
This has attracted A LOT of interest, but inflows into cannabis have plateaud. There's lots of speculation and uncertainty, though it's an interesting space. Definitely, cannabis is not a core holding of his. It's typically to see extreme moves in this ETF and sector. This charges an 0.87% MER. Also consider the smaller SEED-T.
This has attracted A LOT of interest, but inflows into cannabis have plateaud. There's lots of speculation and uncertainty, though it's an interesting space. Definitely, cannabis is not a core holding of his. It's typically to see extreme moves in this ETF and sector. This charges an 0.87% MER. Also consider the smaller SEED-T.
Daniel Straus
Head of ETF Research & Strategy, National Bank Financial
Price
$22.170
Owned
Unknown
DON'T BUY
DON'T BUY
February 5, 2019
Exercise caution. Big move in the underlying companies, so you're always susceptible to a pullback. Shift focus more to the US, where you can get more reasonable valuations. US market is 10x what Canada's is. Money spirals in, and out, of these ETFs. Tough to justify valuations in Canada right now. It's a psychology trade.
Exercise caution. Big move in the underlying companies, so you're always susceptible to a pullback. Shift focus more to the US, where you can get more reasonable valuations. US market is 10x what Canada's is. Money spirals in, and out, of these ETFs. Tough to justify valuations in Canada right now. It's a psychology trade.
Gerard Ferguson
CEO & Portfolio Manager, Jemekk Capital Management
Price
$21.590
Owned
Unknown
COMMENT
COMMENT
December 21, 2018
He is not an expert in cannabis. There will be real industry going forward and some companies will prosper in the long term. The valuations still remain excessive. If he were to participate it would be with Canopy Growth as they have a connection with Constellation Brands in the US.
He is not an expert in cannabis. There will be real industry going forward and some companies will prosper in the long term. The valuations still remain excessive. If he were to participate it would be with Canopy Growth as they have a connection with Constellation Brands in the US.
Don Lato
President, Padlock Investment Management
Price
$14.040
Owned
No
BUY WEAKNESS
BUY WEAKNESS
November 1, 2018
Cannabis. Momentum was stalling in September. There is a short term bounce but there will be choppiness in the short term. He would pick away at these names during this period. The longer term trend is up.
Cannabis. Momentum was stalling in September. There is a short term bounce but there will be choppiness in the short term. He would pick away at these names during this period. The longer term trend is up.
Javed Mirza
Technical analyst, Canaccord Genuity
Price
$18.760
Owned
Unknown
COMMENT
COMMENT
October 4, 2018

Short selling: He has not done much short selling in this space. He tends to be long. If he was going to do it, this would be the vehicle to do it with. There would not be any M&A risk.

Short selling: He has not done much short selling in this space. He tends to be long. If he was going to do it, this would be the vehicle to do it with. There would not be any M&A risk.

Bruce Campbell (2)
President & Portfolio Manager, Stone Castle Investment Management Inc.
Price
$23.540
Owned
Unknown
Showing 1 to 15 of 49 entries